APA (7th ed.) Citation

M, A., A, C., R, B., HY, W., CH, N., D, Y., . . . MA, M. (2026). Projected reduction in major adverse cardiovascular events among high-risk U.S. adults with type 2 diabetes eligible for oral semaglutide: A SOUL trial-based analysis using NHANES (1988-2018) cycles. Cardiovascular diabetology. Endocrinology reports, 12(1), . https://doi.org/10.1186/s40842-026-00299-z

Chicago Style (17th ed.) Citation

M, Al-Jarshawi, Cole A, Bagur R, Wang HY, Ng CH, Yu D, Chew NWS, and Mamas MA. "Projected Reduction in Major Adverse Cardiovascular Events Among High-risk U.S. Adults with Type 2 Diabetes Eligible for Oral Semaglutide: A SOUL Trial-based Analysis Using NHANES (1988-2018) Cycles." Cardiovascular Diabetology. Endocrinology Reports 12, no. 1 (2026). https://doi.org/10.1186/s40842-026-00299-z.

MLA (9th ed.) Citation

M, Al-Jarshawi, et al. "Projected Reduction in Major Adverse Cardiovascular Events Among High-risk U.S. Adults with Type 2 Diabetes Eligible for Oral Semaglutide: A SOUL Trial-based Analysis Using NHANES (1988-2018) Cycles." Cardiovascular Diabetology. Endocrinology Reports, vol. 12, no. 1, 2026, https://doi.org/10.1186/s40842-026-00299-z.